AAMU
BIIB icon

Amundi Asset Management US’s Biogen BIIB Stock Holding History

Amundi Asset Management US’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$148M Sell
529,457
-8,895
-2% -$2.4M 0.11% 197
2020
Q4 		$132M Buy
538,352
+34,888
+7% +$9M 0.11% 200
2020
Q3 		$143M Sell
503,464
-416,527
-45% -$116M 0.15% 143
2020
Q2 		$246M Sell
919,991
-248,921
-21% -$74.8M 0.29% 73
2020
Q1 		$370M Buy
1,168,912
+308,789
+36% +$93.7M 0.64% 29
2019
Q4 		$255M Buy
860,123
+633,249
+279% +$176M 0.3% 83
2019
Q3 		$52.8M Sell
226,874
-2,594
-1% -$604K 0.08% 265
2019
Q2 		$53.7M Sell
229,468
-54,415
-19% -$12.6M 0.04% 303
2019
Q1 		$67.1M Sell
283,883
-208,729
-42% -$65.7M 0.09% 220
2018
Q4 		$148K Buy
492,612
+232,725
+90% +$74.3M 0.14% 119
2018
Q3 		$91.8M Buy
259,887
+58,368
+29% +$20.1M 0.12% 183
2018
Q2 		$58.5M Buy
201,519
+9,866
+5% +$2.77M 0.08% 244
2018
Q1 		$52.5M Sell
191,653
-54,177
-22% -$16.8M 0.08% 243
2017
Q4 		$78.3M Buy
245,830
+199,140
+427% +$63.9M 0.12% 180
2017
Q3 		$14.6M Buy
46,690
+20,400
+78% +$6.04M 0.05% 249
2017
Q2 		$7.13M Sell
26,290
-28,054
-52% -$7.42M 0.02% 363
2017
Q1 		$14.9M Buy
+54,344
New +$15.4M 0.05% 250
2016
Q4 		– Sell
-665
Closed -$208K – 532
2016
Q3 		$208K Sell
665
-434
-39% -$129K ﹤0.01% 535
2016
Q2 		$266K Buy
1,099
+219
+25% +$57.7K ﹤0.01% 548
2016
Q1 		$229K Buy
+880
New +$232K ﹤0.01% 539
2015
Q3 		– Sell
-18,360
Closed -$7.42M – 589
2015
Q2 		$7.42M Sell
18,360
-112
-0.6% -$44.9K 0.03% 385
2015
Q1 		$7.8M Sell
18,472
-121
-0.7% -$47.7K 0.03% 380
2014
Q4 		$6.31M Buy
18,593
+17,524
+1,639% +$5.67M 0.02% 416
2014
Q3 		$354K Sell
1,069
-163
-13% -$53.7K ﹤0.01% 600
2014
Q2 		$388K Sell
1,232
-19
-2% -$5.72K ﹤0.01% 599
2014
Q1 		$383K Sell
1,251
-224
-15% -$71.1K ﹤0.01% 600
2013
Q4 		$413K Sell
1,475
-299
-17% -$77.3K ﹤0.01% 582
2013
Q3 		$427K Buy
+1,774
New +$397K ﹤0.01% 588

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amundi Asset Management US's BIIB Position: Q1 2021 in Review

Amundi Asset Management US reduced its Biogen (BIIB) stake by 1.7% in Q1 2021, selling an estimated $2.4M and leaving 529,457 shares worth $148M. The position accounts for 0.11% of the portfolio, ranked #197.

Amundi Asset Management US first reported a position in BIIB in Q3 2013 and has held it in 28 quarters since. The position peaked at $370M in Q1 2020. 1,093 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

  • Amundi Asset Management US held 529,457 shares of Biogen worth $148M as of Q1 2021.
  • Amundi Asset Management US sold 8,895 Biogen shares in Q1 2021, an estimated $2.4M.
  • Biogen made up 0.11% of Amundi Asset Management US's portfolio in Q1 2021, its #197 holding.
  • Amundi Asset Management US first reported a position in Biogen in Q3 2013 and has held it in 28 quarters since.
  • Amundi Asset Management US's Biogen position peaked at $370M in Q1 2020.
  • 1,093 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.